Kodiak Sciences Inc. (KOD)
| Market Cap | 469.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -312.25M |
| Shares Out | 51.95M |
| EPS (ttm) | -6.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,884,957 |
| Open | 9.05 |
| Previous Close | 8.99 |
| Day's Range | 8.69 - 9.34 |
| 52-Week Range | 4.90 - 131.97 |
| Beta | 1.96 |
| Analysts | Buy |
| Price Target | 10.84 (+19.9%) |
| Earnings Date | Aug 8, 2022 |
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for KOD stock is "Buy." The 12-month stock price forecast is 10.84, which is an increase of 19.91% from the latest price.
News
Why Is Kodiak Sciences Inc. (KOD) Up 88.3% Since Last Earnings Report?
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences to Present at the Jefferies Global Healthcare Conference
PALO ALTO, Calif. , May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high preval...
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture o...
Purpose-built bioconjugation facility in Lonza's Ibex® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence ret...
Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus
Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights
PALO ALTO, Calif., May 10, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Should You Buy Kodiak (KOD) Ahead of Earnings?
Kodiak (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences
PALO ALTO, Calif. , April 29, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to...
Why Is Kodiak Sciences Inc. (KOD) Down 12.7% Since Last Earnings Report?
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
2 Dirt Cheap Biotechs to Buy If You're a Contrarian
Today's losers are selling for peanuts, and they just might become tomorrow's winners.
Kodiak (KOD) Down More Than 80% in Past 3 Months: Here's Why
Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.
Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus
Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Why Kodiak Sciences (KOD) Might Surprise This Earnings Season
Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
PALO ALTO, Calif., March 1, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
Here's Why Kodiak Sciences Inc. (KOD) is Poised for a Turnaround After Losing 82.3% in 4 Weeks
Kodiak Sciences Inc. (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e...
Why Kodiak Sciences Stock Is Cratering Today
A disappointing clinical trial result is weighing heavily on the drugmaker's shares today.
KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?
Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session. The post KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?
Palo Alto Is Leading the Nasdaq Higher, but 1 Biotech Is Getting Crushed Wednesday
Investors are trying to take a longer-term view on the geopolitical situation.
Kodiak Sciences stock loses more than three-quarters of its value after disappointing drug trial results
Shares of Kodiak Sciences Inc. KOD, -4.26% plummeted 76.3% to pace all premarket decliners Wednesday, after the biopharmaceutical company said a Phase 2b/3 trial of its treatment for age-related macular...
Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular ...
PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical ...
Why Kodiak Sciences Shares Are Plunging Today
Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The tria...
Read Why Barclays Analyst Is 'Negatively Biased' On Kodiak Sciences
Barclays has lowered the firm's price target on Kodiak Sciences Inc KOD to $50 from $81 and keeps an Underweight rating on the shares, representing an almost 20% downside. Get the Inside Access Traders ...
Kodiak (KOD) Completes Enrolling Patients in Retina-Based Studies
Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its VEGF inhibitor in patients with DME.
Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabeti...
PALO ALTO, Calif., Feb. 3, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301
Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.